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Edited by Horst FeldmannAbstract The identiﬁcation of the TGFb cytokine signaling
pathway, including membrane receptor serine/threonine kinases
and Smad transcription factors as their substrates, has allowed
the delineation of a process for conversion of these signals into
programs of gene activation and repression that underlie critical
cell fate and developmental decisions. The deconstruction of one
of these responses – the cell cycle arrest response – into its ele-
mental molecular parts has shed light into the mechanisms used
by tumors to evade surveillance and cause metastasis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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As multicellular organism evolved into ever more complex
life forms, so did the need to establish communication and
control among individual cells to maintain order in the organ-
ism. The basic functions of metazoan cells – namely, their pro-
liferation, diﬀerentiation, integration into the tissue structure,
metabolism, and eventual death – fell under the control of a
dense network of secreted polypeptide signals that we call
cytokines, growth factors or polypeptide hormones. The trans-
forming growth factor-b (TGFb) family is particularly promi-
nent among these signals (reviewed in [1,2]). With more than
42 members encoded in the human genome, seven in Drosoph-
ila melanogaster and four in the nematode Caenorhabditis ele-
gans, TGFb and its family members – the nodals, activins,
bone morphogenic proteins (BMPs), myostatin, anti-Muelle-
rian hormone (AMH) and others – control cell division, diﬀer-
entiation, migration, adhesion, organization and programmed
cell death. They may be produced by many cell types, as in the
case of TGFb, or only by a select few, as is the case of myost-
atin. They can play roles from early embryogenesis through
the adult, as in the case of the BMPs, or only during ﬂeeting
moments of organ development, as in the case AMH. Collec-Abbreviations: TGFb, transforming growth factor b; BMP, bone
morphogenetic protein; CDK, cyclin-dependent kinase
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digm of regulatory versatility.
The biology of TGFb itself illustrates this point rather well.
TGFb fosters tissue growth and morphogenesis in the embryo
but it activates cytostatic and cell death processes that main-
tain homeostasis in mature tissues. Cancer cells seek to avert
these growth inhibitory eﬀects by the accumulation of muta-
tions that attenuate or altogether cancel TGFb signaling. Most
insidiously, but not infrequently, tumors cells may corrupt the
TGFb pathway, turning it from tumor suppressor into a medi-
ator of metastasis. Understanding the mechanisms that under-
lie these eﬀects, and how cells turn these signals into coherent
responses, has come from the elucidation of a TGFb signaling
pathway that controls gene expression. This level of under-
standing is providing new insights into the organization of
transcriptional responses to extracellular signals, and the vul-
nerability of this network to cancer-causing lesions. Here, we
review these advances, and discuss a framework for future
progress.2. TGFb signaling pathways
The signaling pathway that conveys TGFb inputs from
membrane receptors to target genes is well established
(Fig. 1). TGFb binds to receptor on the cell surface forming
a bi-dimeric receptor complex, that is, a complex of two pairs
of subunits known as receptor type I (TbR-I, also known as
ALK5) and type II (TbR-II). A membrane-anchored proteo-
glycan, known as type III receptor or betaglycan, aids this pro-
cess by capturing TGFb for presentation to the signaling
receptors I and II [3]. This system was originally identiﬁed
through a combination of biochemical and genetic approaches
[4–6]. Molecular cloning showed the type I and II subunits to
be transmembrane threonine/serine kinases and TGFb [7–9].
The human genome encodes seven type I receptors (ALKs
1–7) and ﬁve type II receptors (ActR-IIA, ActR-IIB, BMPR-
II, AMHR-II and TbR-II) that are paired in diﬀerent combi-
nations as receptor complexes for the various members of
the TGFb family. The type I receptors are distinguished by
the presence of a 30-amino regulatory segment or ‘‘GS region’’
located immediately upstream of the kinase domain. In the li-
gand-bound complex, the type II receptor phosphorylates ser-
ine and threonine residues in the GS region of the type I
receptor, which then propagates the signal [10]. Phosphoryla-
tion switches this region from serving as a docking site for
an inhibitor, the protein FKBP12, to a docking site for its sub-
strates, the Smad family of transcription factors [11,12].blished by Elsevier B.V. All rights reserved.
Fig. 1. The TGFb signaling pathway. Transforming growth factor
(TGFb) binds to the Type II receptor and recruits Type I, whereby
Type II receptor phosphorylates and activates Type I. The Type I
receptor, in turn, phosphorylates receptor-bound Smad (Smad2/3)
transcription factors at the carboxy-terminal SXS motif, releasing
them from retention in the cytoplasm and allowing them to translocate
into the nucleus. Smad4 acts as a common partner of activated Smads
to help execute their function. Smad proteins continuously undergo
nucleocytoplasmic shuttling by interacting with nuclear-pore com-
plexes. Once in the nucleus, activated Smad proteins form ﬁnal
complexes that regulate target gene transcription, generating approx-
imately three hundred early gene responses.
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tling by direct interactions with the nuclear pore complex
[13,14]. In the absence of phosphorylation, Smads are trans-
criptionally inert. The type I receptors for TGFb, activin, no-
dal and myostatin (ALKs 4, 5 and 7) phosphorylate Smads 2
and 3, whereas the BMP and AMH type I receptors (ALKs
1, 2, 3 and 6), phosphorylate Smads 1, 5 and 8. Receptor-med-
iated phosphorylation occurs at the carboxy-terminal motif
Ser-Xxx-Ser and induces the accumulation of Smad proteins
in the nucleus [15–17]. The phosphorylated motif pSer-Xxx-
pSer serves as a docking site for Smad4 [18,19], which is not
a receptor substrate but an essential component of the result-
ing transcriptional complexes [20,21]. Smad stimulation typi-
cally leads to hundreds of immediate gene activation or
repression responses.
X-ray crystallographic studies of TGFb receptors and Smad
proteins have shed much light into the mechanisms of interac-
tion and activation of these proteins [21]. Smad proteins con-
sist of two globular domains or MH1 and MH2 domains,
respectively, connected by a ﬂexible linker region. The MH1
domain is responsible for DNA-binding [22] whereas the
MH2 domain establishes contacts with anchors for cytoplas-
mic retention [18], receptors for activation [12], nucleoporins
for nucleocytoplasmic translocation [23], and partner Smads
and other nuclear factors for the assembly of transcriptional
complexes [19].Activated Smad proteins are recognized by protein phospha-
tases and ubiquitin ligases that terminate the signaling process.
Under conditions of TGFb stimulation, Smads constantly un-
dergo cycles of receptor-mediated phosphorylation and pho-
spatase-mediated dephosphorylation, shuttling in and out of
the nucleus by processes [24]. Recently, progress has been
made in identifying Smad phosphatases. Pyruvate dehydroge-
nase phosphatase, an enzyme whose only known substrate was
this mitochondrial enzyme, has been identiﬁed by RNAi li-
brary screening to trigger dephosphorylation of Smad1 in Dro-
sophila [25]. Similarly, an expression library screening in
Xenopus and complementary experiments based on RNAi-
mediated inactivation in human cells, have led to the identiﬁ-
cation of the SCP family of nuclear protein phosphatases
and mediators of Smad1 dephosphorylation in vertebrate spe-
cies [26]. The Smurf family of HECT domain, WW-repeat
ubiquitin ligases mediate ubiquitination and proteasome-
dependent degradation of Smad proteins [27]. Evidence exists
that receptor-activated Smads undergo selective ubiquitin-
mediated degradation [28]. However, the involvement of
Smurfs in this process and the manner in which phosphory-
lated Smads would be recognized for degradation remain as
open questions. Beyond the core components of the Smad sig-
naling pathway described above, many factors have been iden-
tiﬁed that tightly regulate the activity of each step in this
powerful signaling process (for reviews see [29,30]).
Genetic studies have hinted that certain Smad-dependent ef-
fects may not require Smad4 [31–33]. Indeed, a non-canonical
version of this pathway that does not involve Smad4 has been
recently identiﬁed that involves the ubiquitous nuclear protein
transcriptional intermediary factor 1c (TIF1c). TIF1c selec-
tively binds to receptor-phosphorylated Smad2/3 in competi-
tion with Smad4 [34]. In human hematopoietic stem/
progenitor cells, which respond to TGFb with inhibition of
proliferation and stimulation of erythroid diﬀerentiation,
TIF1c mediates the diﬀerentiation response, Smad4 mediates
the antiproliferative response and Smad2/3 participate in both
responses. Thus, the TGFb/Smad pathway controls hemato-
poietic cell fate through the complementary Smad2/3-TIF1c
and Smad2/3-Smad4 eﬀector arms [34].
Smad signaling is essential for most, but not all, TGFb
gene responses. TGFb has been shown to activate other
mediators such as the mitogen-activated protein kinases
(MAPKs) ERK, Jun N-terminal kinase (JNK), p38, PI3K ki-
nases, PP2A phosphatases and Rho family members (re-
viewed in [35]). Unlike the Smad pathway, however, these
alternative pathways are activated by TGFb in a cell type
dependent manner, and their biochemical links to the acti-
vated receptors are largely unknown. Exceptions are the epi-
thelial polarity protein Par6 which is directly regulated by the
TGFb type II receptor to control epithelial cell plasticity [36],
and LIM kinase, which directly interacts with the BMP type
II receptor to control actin cytoskeleton dynamics and den-
drite formation [37,38].3. The transcriptional response to TGFb
Once the TGFb signal is engaged, how does TGFb signaling
activate certain genes while repressing others in the same cell,
at the same time? And, how do activated Smads regulate diﬀer-
ent genes in diﬀerent cell types? A general framework for the
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ognition that Smads function in association with diﬀerent pro-
tein partners [39]. Each Smad-partner combination targets a
particular subset of genes depending on the DNA binding
speciﬁcity of this combination, and recruits either transcrip-
tional co-activators or co-repressors. Members of many fami-
lies of DNA binding proteins have been conscripted to act as
Smad cofactors in this fashion. These include the FOX,
HOX, RUNX, E2F, AP1, CREB/ATF, Zinc-ﬁnger and other
families. The availability of such cofactors may vary depending
on the cell type, partly determining the gene responses to
TGFb in each cell type [30,40].
Why should Smads require cofactors in order to achieve
high aﬃnity and selectivity for target genes? The answer is pro-
vided by the properties of the Smad-DNA contact, whose de-
tails have been revealed by X-ray crystal structure analysis
[22]. The Smad MH1 domain recognized the sequence CAGA
[41] as well as certain GC-rich sequences [42]. However, the
aﬃnity of these interactions is too low for eﬀective binding
in vivo. By associating with DNA-binding cofactors, and thus
assembling transcriptional complexes with multiple DNA
binding entities of diﬀerent cognate sequence, Smads achieve
target gene speciﬁcity by requiring that the target promoter
present the cognate sequences in the proper distance and orien-
tation. Smads also achieve pathway speciﬁcity by requiring
that the cofactors recognize Smad2/3 or Smad1/5/8, and cell
type speciﬁcity by requiring that a given cell express a particu-
lar cofactor in order to be competent to target a speciﬁc gene.
The molecular mechanisms by which Smad-coactor com-
plexes are assembled, and the speciﬁc role of the Smads in
the resulting complex vary [30]. For some gene responses,Fig. 2. The TGFb transcriptional program and its alterations in cancer. The
at the level of the TGFb signaling pathway in distinct types of human cancers
to the biological responses that they mediate. Highlighted in yellow are th
complexes. Highlighted in red are gene responses repressed by TGFb and inthe transcriptional activation or repression through a Smad
complex is direct, involving the binding of a pre-existing cofac-
tor to the core phosphoSmad-Smad4 complex [43,44]. For oth-
ers, transcriptional regulation requires a ‘‘self-enabled’’
process whereby activated Smads induce the expression of a
gene whose product goes on to associate with Smads to medi-
ate another set of gene responses [45]. Identifying Smad part-
ners therefore has become essential for delineating cell-
speciﬁc programs of TGFb action and their integration into
the signaling networks of the cell.4. Organization of the TGFb transcriptional programs
Genome-wide transcriptomic analysis of the TGFb response
in various cell types has demonstrated that stimulation leads to
the rapid activation or repression of a few hundred gene re-
sponses in any given cell type (Fig. 2) [46,47]. To generate this
large set of gene responses, it is thought that the pool of acti-
vated Smad protein is shared among diﬀerent partner cofac-
tors, each Smad-cofactor combination mediating a subset of
gene responses. TGFb gene responses could therefore be clas-
siﬁed by groups of genes that are jointly controlled by a given
Smad-cofactor combination. A group of genes that are simul-
taneously regulated by a common signal is denoted as a ‘‘syn-
expression group’’. Such gene responses are thought to
orchestrate the successful completion of developmental pro-
cesses or stress responses [48]. The identiﬁcation of such
groups is a focus of current eﬀorts to delineate and rationalize
the organization of TGFb transcriptional program in each cell
type.schematic shown on the left depicts mutations or alterations that occur
. On the right, TGFb target genes in epithelial cells are listed according
e TGFb transcriptional gene responses that depend on FoxO-Smad
green gene responses induced by TGFb.
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group has been provided by recent studies on TGFb gene re-
sponses mediated by Smad proteins in combination with FoxO
transcription factors [49]. FoxO transcription factors are mem-
bers of the Forkhead family and play a prominent role in the
control and integration of cellular and organismal growth,
development, metabolism and longevity under caloric restric-
tion [50,51]. Building on the ﬁnding that a FoxO-Smad com-
plex mediates the transcriptional activation of p21CIP1 in
response to TGFb [52], RNAi-mediated knockdown of FoxO
factors (FoxO1, 3 and 4) revealed the requirement of these fac-
tors for at least eleven of the 115 rapid gene activation re-
sponses triggered by TGFb in cultured human keratinocytes
[49]. This group of 11 genes is functionally quite diverse. In
addition to the cyclin-dependent kinase (CDK) inhibitor
p21CIP1, they include another CDK inhibitor, p15INK4b, sev-
eral mediators of stress responses (GADD45A, GADD45B and
IER1) and mediators of adaptive responses (CTGF, JAG-
GED1, LEMD3, SGK1, CDC42EP3 and OVOL1) (Fig. 2).
Activation of all these genes by TGFb requires FoxO,
Smad2/3 and Smad4 factors and involves their association
and joint binding to the target promoters on stimulation by
TGFb.
Further analysis has revealed the existence of a second layer
of organization. FoxO-Smad target genes diﬀer in their addi-
tional requirement of C/EBPb [49]. C/EBPb is a transcription
factor that can positively and negatively regulate gene expres-
sion [53–55]. Based on these examples, one can envision a ser-
ies of interconnecting groups of TGFb gene responses.
Diﬀerent outcomes of the TGFb response in diﬀerent cellular
contexts can result in this manner.5. Smads as nodes for signaling integration
The matrix organization of the Smad signaling system has
the ability to integrate cellular signals controlling the activity
of Smad cofactors in addition to signals that directly regulate
the activity of the Smad themselves. Smad regulation by di-
verse inputs occurs through direct phosphorylation of the lin-
ker region connecting the MH1 and MH2 domains [56]. This
region contains multiple Ser-Pro and Thr-Pro residues that
are phosphorylated by endogenous MAPK kinases [57,58], cal-
cium-calmodulin-dependent protein kinase II [59] as well asFig. 3. The TGFb cytostatic program. Shown are the transcriptional compo
cells. Indicated in red are the targets of alterations present in distinct types of
Cofactor complexes converging on the target genes that mediate cell cycle aCDKs [60]. These inputs attenuate the nuclear accumulation
and transcriptional activity of Smads, having a negative im-
pact on their signaling function, with important physiological
consequences [61,62]. However, the mechanism by which phos-
phorylation of the Smad linker region exerts such eﬀects re-
mains a mystery wanting unraveling [56].
Smad DNA-binding partners provide another venue for reg-
ulatory inputs controlling the activity of the Smad signaling
pathway. For instance, FoxO factors are under the negative
control by the PI3Kinase/AKT pathway and other protein ki-
nases [50,51,63]. Phosphorylation of the FoxO proteins leads
to their eviction from the nucleus and, in some cases, to their
proteosome-mediated degradation [50]. Oxidative stress medi-
ates FoxO acetylation. The protein deacetylases Sir2 and
HDAC reverse this reaction preventing FoxO-dependent
induction of pro-apoptotic gene responses [64,65]. These regu-
latory inputs may likewise aﬀect the ability of FoxO factors to
function as Smad partners in the cellular response to TGFb.
Indeed, FoxO phosphorylation by Akt/PKB in response to
growth-promoting signals attenuates the induction of
p21Cip1 by TGFb [52]. Smad complexes therefore act as nodes
for signaling integration, a property that provides critical plas-
ticity to the TGFb response. At the same time, this represents
the Achilles’ heel of the TGFb pathway, making it vulnerable
to disruption in cancer and other disorders, as we shall see be-
low.6. TGFb cytostatic program
One of the primary functions of TGFb is to limit epithelial
proliferation and induce diﬀerentiation through a program of
cytostatic gene responses (Fig. 3). Cell cycle arrest in response
to TGFb occurs at the ‘‘restriction point’’ in late G1 phase, by
inhibition of CDKs that phosphorylate pRB and other compo-
nents [6,66]. TGFb can activate cytostatic gene responses at
any stage of the cell cycle. However, since cytostatic gene re-
sponses primarily target G1 events, cells that have already
passed the restriction point will not arrest in the ongoing cycle
(Fig. 3).
Initial studies focusing on candidate genes, and more recent
studies examining the transcriptional response by microarray
in skin, lung and mammary epithelial cells have elucidated
the set of TGFb gene responses that orchestrate the cytostaticnents underlying the principal TGFb cytostatic responses in epithelial
human cancers either at the level of signal transduction events or Smad-
rrest.
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the CDK inhibitors p21Cip1 [67] and p15Ink4b [68]. Concom-
itantly TGFb induces repression of c-Myc [69], a transcription
factor that promotes cell growth and proliferation, and ID1, 2
and 3 [45], which are nuclear factors that prevent cell diﬀeren-
tiation. Thus, TGFb signaling applies brakes of CDKs and
de-accelerates proliferative functions. This dual action is also
observed in hematopoietic progenitors cells, in which TGFb
induces expression of the p57Kip2 CDK inhibitor and re-
presses c-Myc expression [70]. Cooperatively, these set of re-
sponses provide a coherent program for the arrest of the cell
cycle (Fig. 3).
The interplay between TGFb-inducible CDK inhibitors and
their targets involves another member of the family, p27Kip1.
In fact, p27Kip1 was the ﬁrst identiﬁed mediator of the CDK
inhibitory eﬀect of TGFb [71,72]. p27Kip1 levels are increased
little if at all in response to TGFb. Rather, p27Kip1 is titrated
away from its target Cdk2 by binding to cyclin D-Cdk4/6 com-
plexes. Upon induction of p15Ink4b expression by TGFb,
p15Ink4b displaces p27Kip1 from Cdk4/6, and p27Kip1
moves on to inhibit Cdk2 [73].
Transcriptional activation of p15INK4b and p21CIP1, and
transcriptional repression of c-MYC and ID genes by TGFb
are Smad-dependent responses [43,45,49]. Progress in elucidat-
ing Smad transcriptional mechanisms has enabled the identiﬁ-
cation of Smad cofactors that mediate each of these gene
responses. An activated Smad-FoxO transcriptional complex
mediates p21CIP1 induction [52] whereas induction of
p15INK4b requires a Smad-FoxO-C/EBPb transcriptional
complex [49] (Fig. 3). Smad-E2F4/5-C/EBPb and Smad-
ATF3 complexes target c-MYC and ID1 for repression, respec-
tively [43,45,49] (Fig. 3). c-Myc plays additional coordination
in this process: when present at high levels as in mitogen-stim-
ulated cells, c-Myc binds to the p21CIP1 and p15INK4b pro-
moters via the zinc ﬁnger protein Miz-1, interfering with
transcriptional activation of these genes by TGFb, the tu-
mor-suppressor p53, and other signals. c-Myc downregulation
by TGFb relieves this interference, rendering p21CIP1 and
p15INK4b competent for activation [74–76].
The TGFb cytostatic program provides a remarkable
example of a coordinated cellular response through a set
of concerted biochemical interactions. FoxO factors coordi-
nate induction of two CDK inhibitors by Smads whereas
C/EBPb coordinates the induction of p15INK4b and the
repression of c-MYC by Smads. The induction of CDK
inhibitors is conditional on a decline in c-Myc expression.
p27Kip1 cooperates with p15Ink4b to bring about inhibition
of the two key G1 CDKs, and CDK inhibition cooperates
with removal of c-Myc and Id functions to suppress cell pro-
liferation.7. TGFb signaling as a tumor suppressor pathway
Alterations in TGFb signaling are responsible for various
somatic and heritable disorders in humans [77]. One of the
most important pathologies of the TGFb system is its malfunc-
tion in cancer. The cytostatic and diﬀerentiative eﬀects of
TGFb are a barrier to tumor emergence and progression.
Therefore, it is not surprising that loss of these responses is a
hallmark of cancer. Evasion of cytostasis is a strong selectiveadvantage, and tumors cells achieve it through various mech-
anisms that have only recently come to light (Fig. 3).
Colon cancers with microsatellite instability (MSI) almost
invariably accumulate replication errors in the coding se-
quence of the TGFb type II receptor. These mutations are gen-
erated by insertion or deletion of adenines in a 10-bp
polyadenine track, leading to expression of a truncated, inac-
tive receptor product [78]. Similar mutations occur in MSI gas-
tric tumors and gliomas [79]. Mutational inactivation of the
TGFb type II receptor also occurs in a proportion of microsat-
ellite-stable colorectal cancers. In this case the mutations aﬀect
mostly the receptor kinase domain [80]. Mutations in type I
receptors are less frequent but are also observed in ovarian,
breast, and pancreatic cancers [81–83]. Inherited mutations
in the BMP type I receptor BMPR-IA (ALK3) cause juvenile
polyposis [84]. At the level of the Smads, inactivating muta-
tions and deletions in the SMAD4 locus occurs in more than
half of pancreatic cancers and in a smaller proportion of gas-
trointestinal cancers [80,82]. Thus, the central components of
the TGFb signaling pathway suﬀer inactivating mutations in
human cancer, validating their role as bona ﬁde tumor sup-
pressors [77,85,86] (Figs. 2 and 3).
The tumor suppressor nature of these TGFb signaling com-
ponents has been recapitulated in various genetically engi-
neered mouse models based on ablation of TGFb ligands,
receptors and Smads (reviewed in [87]). Interestingly, condi-
tional ablation of the TGFb type II receptor gene in stromal
ﬁbroblasts in the mouse results in development of aggressive
carcinomas of the stomach and prostate [88]. Conversely,
expression of a dominant negative TGFb receptor construct
in mammary or skin epithelium promotes primary tumor for-
mation while overexpression of TGFb1 inhibits primary tumor
outgrowth.
In other types of cancer, however, TGFb plays a complex
dual role, as ﬁrst demonstrated by a multistage skin carcino-
genesis model in keratinocyte-speciﬁc TGFb transgenic mice
[89]. These mice develop fewer early-stage skin papillomas in
response to carcinogen treatment, but sustain more aggressive
spindle carcinomas compared to control mice. At early stages
of epithelial neoplasia the TGFb pathway functions as a tumor
suppressor, inhibiting primary tumor growth. At later stages of
carcinogenesis, however, tumor cells that have developed the
ability to bypass these tumor suppressor functions may use
TGFb for tumor progression. Indeed, aggressive human tu-
mors that are resistant to the growth inhibitory eﬀects of
TGFb often retain functional TGFb receptors and Smad activ-
ity. For example, breast cancer and glioblastoma cells often
lose TGFb cytostatic responses without inactivation of TGFb
receptors or Smad proteins [90,91]. When this occurs, tumor
cells may utilize their TGFb system to induce gene responses
that promote tumor growth [92], invasion [85,86], evasion of
immune surveillance [93–95] and metastasis [86,87,96,97]
(Fig. 4A).8. Selective evasion of TGFb-dependent cytostasis
Identifying the mechanisms for selective evasion of the cyto-
static responsiveness to TGFb in cancer is important, as this
capacity enables the corrupt use of the TGFb pathway in tu-
mor progression. Loss of the ultimate eﬀector of TGFb cyto-
Fig. 4. Steps of TGFb action during cancer progression. (A) (a) TGFb limits the growth of normal epithelium and early-stage tumors. (b) Loss of
TGFb cytostatic action can occur via mutation or loss of TGFb receptors, Smads or by speciﬁc loss of the TGFb cytostatic responses. Tumor cells
that have lost these responses many undergo epithelial-mesenchymal transformation in response to TGFb and become more invasive. Concurrently,
these cells may use TGFb to evade the immunosuppressive environment and induce angiogenesis and systemic spread. (c) Adherence of tumor cells to
the endothelium and/or extravasation of tumor cells at sites of metastasis, such as lung, can be augmented by TGFb signaling. TGFb also stimulates
the expression of genes such as interleukin-11 and connective tissue growth factor (CTGF), which promote osteolytic bone metastasis by breast
cancer cells. (B) TGFb activated and repressed genes in cell lines derived from mammary epithelium (MCF-10A) or breast cancer (MDA-MB-231).
Responses of these genes to TGFb in each cell line are represented by diﬀerent shades of red (degrees of activation) or blue (degrees of repression) in
the dendrogram.
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TGFb only in some cases [6,98], while the loss of other inter-
connected tumor suppressors including p53, p16Ink4a, ARF
or p27Kip1 has little eﬀect. Due to functional redundancies,
TGFb remains a potent growth inhibitor in cells that lack
p15Ink4b [99] or the c-Myc response [43]. Interestingly, how-
ever, the combined loss of these two gene responses correlates
with evasion of cytostasis in breast cancer cell lines [46].
The identity of speciﬁc defects that interfere with TGFb
cytostatic responses while sparing many others has begun to
emerge from studies on glioblastoma [52] and breast cancer
[49] (Fig. 4B). Glioblastomas typically contain a hyperactive
PI3K/Akt pathway due to gene ampliﬁcation or activating
mutations in the phosphatidyl inositol kinase PI3K, or inacti-
vating mutations in the phosphatidyl inositol phosphatase
PTEN [100]. Since PI3K through Akt/PKB negative controls
the activity of FoxO factors [50,51,63], the hyperactivity of this
pathway in glioblastoma inhibits FoxO factors from serving as
Smad partners in the induction of p21Cip1 [52]. The activity of
FoxO factors as Smad partners can also be inhibited by the tel-
encephalic development factor FoxG1 [52]. FoxG1 is essential
for neuroepithelial development during telencephalon forma-
tion in the mouse [101] and suppresses early cortical cell fate
[102,103]. Neuroepithelial progenitor cells from foxg1 null
mice, but not their heterozygous counterparts, respond to
TGFb with p21Cip1 induction and growth arrest [52]. Thus,
FoxG1 and PI3K collude in preventing TGFb from triggering
p21Cip1 expression and cytostasis in glioblastoma cells. Freedfrom cytostatic responsiveness, glioblastoma cells can respond
to TGFb with production of the autocrine mitogen PDGF
[104], turning TGFb from a tumor suppressor into a tumor
growth-promoter.
A diﬀerent mechanism for evasion of TGFb cytostatic gene
responses appears to operate in metastatic breast cancers. In
mammary and other epithelial cell types, the induction of
p15INK4b and the repression of c-MYC by complexes yet be
completely described in response to TGFb are essential to
maintain the TGFb cytostatic function (Fig. 3). In these cells,
TGFb receptors and Smad proteins remain intact and capable
of inducing many other gene responses in these metastatic
cells. The remaining responses include induction of interleu-
kin-11 (IL11) and connective-tissue growth factor (CTGF),
two genes that have been independently implicated in bone
metastatsis [96,105] (Fig. 4B).9. Immune evasion and metastatic expansion
Freed from growth inhibitory constraints, tumor cells can
use TGFb with impunity to foster tumor progression. Two
advantages that tumors cells may derive in this fashion are eva-
sion of immune surveillance and metastatic colonization of
vital organs.
TGFb is the most powerful physiological immunosuppres-
sor in mammals [93]. Genetically manipulated mice that lack
TGFb die due to massive systemic inﬂammation and autoim-
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TGFb controls T cell homeostasis by directly inhibiting both T
cell proliferation and activation, and by also inhibiting presen-
tation of antigens on antigen-presenting cells [93]. Therefore,
the loss of tumor speciﬁc TGFb-mediated cytostasis allows
the tumor to utilize TGFb to profoundly alter the tumor
microenvironment and host immune response. TGFb released
or activated by tumor cells acts on CD8+ cytotoxic T lympho-
cytes (CTL) to suppress the expression of ﬁve cytolytic media-
tors. In the presence of TGFb, CTLs fail to express the protein
perforin that intercalates into target tumor cells to form mem-
brane pores, the apoptotic activators granzyme A and B that
ﬂow into the tumor cell through these pores, the proapoptotic
mediator FasL, and the proinﬂammatory cytokine IFNc. Pre-
vented from expressing these cytolytic mediators, CTLs lose
their tumor ﬁghting capacity, allowing unfettered tumor
growth [94] (Fig. 4A).
Tumor cells that have selectively lost the TGFb cytostatic
response may turn their remaining responsiveness in favor
of metastasis. In a manifestation of the dual role of TGFb
in cancer in metastatic mammary tumors, a constitutively
activated TGFb type I receptor transgene delayed the growth
of Neu-driven mammary tumors in mice but accelerated the
formation of lung metastasis in the same animals. The pres-
ence of constitute TGFb signals in the tumor cells enhanced
their extravasation into the lung parenchyma [107]. Likewise,
TGFb enhances the ability of MDA-MB-231 human breast
cancer cells to form osteolytic bone metastasis in athymic
nude mice [108]. These cells have typically lost TGFb cyto-
static responses [46] (Fig. 4B). A group of genes whose over-
expression mediates bone metastasis in MDA-MB-231 cells
has been deﬁned. Among these genes are cell-surface and
secretory products that mediate homing to the bone marrow,
facilitate invasion, and promote bone lysis by osteoclasts. At
least two of these genes, IL11 and CTGF, are responsive to
TGFb [96,105] (Fig. 4B). A combination of immunohisto-
chemical analysis of human breast cancer bone metastases,
and functional imaging of the Smad pathway in a mouse
xenograft model, has provided evidence for active Smad sig-
naling in human and mouse bone metastatic lesions. RNAi-
mediated depletion showed that Smad4 contributes to the
formation of osteolytic bone metastases and to be essential
for the induction of IL11 and CTGF. Thus, these ﬁndings
provide functional evidence for a switch of the Smad path-
way, from tumor-suppressor to pro-metastatic, in the devel-
opment of breast cancer bone metastasis [96].10. Conclusion
The delineation of the Smad signaling pathway and the iden-
tiﬁcation of cofactors that determine the repertoire of gene re-
sponses and the overall eﬀect of TGFb in each cell type have
provided a welcomed measure of logic order to an otherwise
bewildering multifunctional pathway. The identiﬁcation of
Smad partner proteins that are essential for key cell-speciﬁc
programs of TGFb action, including the cytostatic program
in epithelial cells and the cytotoxic program in lymphocytes,
are providing new insights into the organization of transcrip-
tional responses and the vulnerability of this network to can-
cer-causing lesions. Building on these advances, the ﬁeld isset to seek the identiﬁcation of genes and mechanisms that
mediate many other physiological aspects of TGFb action.
Current eﬀorts to develop drugs that speciﬁcally target the
TGFb pathway are aided by this level of understanding, and
may reward us with some progress in the ﬁght against diseases
of this pathway.
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